2.要約四半期連結財務諸表及び主な注記
(1)要約四半期連結財政状態計算書
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2025年3月31日) | | 当第1四半期連結会計期間 (2025年6月30日) |
資産 | | | | | |
流動資産 | | | | | |
現金及び現金同等物 | | | 55,241 | | 58,277 |
営業債権及びその他の債権 | | | 42,292 | | 42,452 |
棚卸資産 | | | 42,500 | | 45,700 |
その他の金融資産 | | | 3,244 | | 3,654 |
その他の流動資産 | | | 6,461 | | 7,583 |
流動資産合計 | | | 149,740 | | 157,667 |
非流動資産 | | | | | |
有形固定資産 | | | 34,531 | | 34,391 |
無形資産 | | | 48,315 | | 47,749 |
使用権資産 | | | 2,781 | | 2,474 |
その他の金融資産 | | | 39,492 | | 37,512 |
繰延税金資産 | | | 5,597 | | 6,642 |
その他の非流動資産 | | | 3,177 | | 3,186 |
非流動資産合計 | | | 133,897 | | 131,957 |
資産合計 | | | 283,637 | | 289,625 |
| | | | | |
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2025年3月31日) | | 当第1四半期連結会計期間 (2025年6月30日) |
負債及び資本 | | | | | |
負債 | | | | | |
流動負債 | | | | | |
営業債務及びその他の債務 | | | 16,857 | | 18,192 |
その他の金融負債 | | | 305 | | 299 |
リース負債 | | | 1,348 | | 1,224 |
未払法人所得税 | | | 4,705 | | 3,451 |
その他の流動負債 | | | 7,100 | | 8,796 |
流動負債合計 | | | 30,316 | | 31,964 |
非流動負債 | | | | | |
その他の金融負債 | | | 233 | | 233 |
リース負債 | | | 1,374 | | 1,197 |
退職給付に係る負債 | | | 4,313 | | 4,336 |
その他の非流動負債 | | | 59 | | 59 |
非流動負債合計 | | | 5,980 | | 5,826 |
負債合計 | | | 36,297 | | 37,791 |
資本 | | | | | |
資本金 | | | 5,174 | | 5,174 |
資本剰余金 | | | 4,491 | | 4,514 |
利益剰余金 | | | 222,640 | | 228,538 |
自己株式 | | | △2,459 | | △2,459 |
その他の資本の構成要素 | | | 17,181 | | 15,754 |
親会社の所有者に帰属する持分合計 | | | 247,028 | | 251,521 |
非支配持分 | | | 312 | | 312 |
資本合計 | | | 247,340 | | 251,834 |
負債及び資本合計 | | | 283,637 | | 289,625 |
E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2025-04-012025-06-30Q12026-03-312024-04-012024-06-302025-03-311falsefalsefalse451602024-03-31451602025-03-31451602024-04-012024-06-30451602024-06-30451602025-04-012025-06-30451602025-06-30451602025-08-07451602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-03-31jpigp_cor:ShareCapitalIFRSMember451602024-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-03-31jpigp_cor:TreasurySharesIFRSMember451602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012024-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-04-012024-06-30jpigp_cor:ShareCapitalIFRSMember451602024-04-012024-06-30jpigp_cor:CapitalSurplusIFRSMember451602024-04-012024-06-30jpigp_cor:RetainedEarningsIFRSMember451602024-04-012024-06-30jpigp_cor:TreasurySharesIFRSMember451602024-04-012024-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-04-012024-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-04-012024-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-04-012024-06-30jpigp_cor:NonControllingInterestsIFRSMember451602024-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-06-30jpigp_cor:ShareCapitalIFRSMember451602024-06-30jpigp_cor:CapitalSurplusIFRSMember451602024-06-30jpigp_cor:RetainedEarningsIFRSMember451602024-06-30jpigp_cor:TreasurySharesIFRSMember451602024-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-06-30jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-06-30jpigp_cor:ShareCapitalIFRSMember451602025-04-012025-06-30jpigp_cor:CapitalSurplusIFRSMember451602025-04-012025-06-30jpigp_cor:RetainedEarningsIFRSMember451602025-04-012025-06-30jpigp_cor:TreasurySharesIFRSMember451602025-04-012025-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-04-012025-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-04-012025-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-04-012025-06-30jpigp_cor:NonControllingInterestsIFRSMember451602025-06-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-06-30jpigp_cor:ShareCapitalIFRSMember451602025-06-30jpigp_cor:CapitalSurplusIFRSMember451602025-06-30jpigp_cor:RetainedEarningsIFRSMember451602025-06-30jpigp_cor:TreasurySharesIFRSMember451602025-06-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-06-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-06-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-06-30jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012024-06-30jpcrp_cor:ReportableSegmentsMember451602024-04-012024-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602024-04-012024-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602024-04-012024-06-30jpcrp_cor:ReconcilingItemsMember451602025-04-012025-06-30jpcrp_cor:ReportableSegmentsMember451602025-04-012025-06-30tse-qcediffr-45160:MedicineReportableSegmentMember451602025-04-012025-06-30tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602025-04-012025-06-30jpcrp_cor:ReconcilingItemsMemberxbrli:pureiso4217:JPYxbrli:sharesiso4217:JPY